One of the best ways to encounte out what's brand-new and hot in diabetes technology is to follow the industry's "earnings calls." These quarterly webcast sessions are designed to update investors on merchandise pipelines you said it stage business is expected to go in the coming months — so essentially they're sneak peeks into what we patients can expect inoperative the road.

This past week, three earnings calls revealed some very word-worthy tidbits — from Insulet, In tandem Diabetes Care and Dexcom. Hera's what we well-read about each on the business and new-product front:

Patronage Advance: Insulet appears to be doing well on the business organization English these days. New patient starts were up 20% this past year, while fresh pediatric patients were up a full 30% complete the previous year. So more patients are starting the OmniPod than ever before, information technology seems. Insulet Chief operating officer Slick Sullivan says the company at once has a total 85,000 OmniPod users, as of the end of 2015.

Insulet sold its Locality Diabetes Business (the mail order medical supply company it acquired a few years ago) to Familiarity Medical early this month, pregnant those OmniPod customers who used Neighborhood Diabetes as a durable medical equipment supplier will instantly be switched to Liberty.

Higher Centralized-Insulin Pods: Insulet's excited about its partnership with Eli Lilly for developing OmniPod devices that will receive some the concentrated U-200 and U-500 insulins inside. They're queuing up a clinical study the U-500 rendering now, and already possess a third of the required patients signed risen. Insulet expects both of these new Pods to be available in the future 2 operating theatre 3 eld, offering more choice for PWDs World Health Organization English hawthorn need more insulin.

Mobile-Friendly OmniPod: Apparently, the company spent much of the past year doing marketing research to learn more about what patients privation, don't want, and how they can ameliorate their offerings going forward.

By middle-class, Insulet plans to plunge a mobile app that has basic functions like allowing customers to society supplies, find training resources, and generally "enhance the customer user experience." We'Re told the ship's company isn't ready to unveil the app's gens yet, but the initial launching volition be iPhone compatible, followed by Android compatibility to be released towards the end of the year.

This combines with the recently proclaimed Insulet Provided Glooko system, which is a fancy name for OmniPod information being merged into the Glooko information-viewing program. That began in January and gives customers a way to use Glooko's Mobile apps to video display to track their diabetes data from the OmniPod and combine that with data from other devices.

All of this changeful-friendliness is a function of the new "Member Insulet" campaign, aimed at shifting the focus to a digital platform and move the OmniPod restrainer functionality from the existing PDM to an app – eventually making way for a smaller and less complex handheld device (that testament likely sole suffice as a patronage, if information technology follows the Dexcom cagey CGM technical school pathway).

Based on primal discussions with regulators, Insulet is not yet sure what all can be put onto the first-generation mobile app, especially American Samoa it relates to insulin dosing functions. Merely the company wants to move as quickly as possible from the PDM to the mobile phone app, cutting kill the size of its PDM so it only serves atomic number 3 a backup gimmick – as that's what their late market research has told Insulet customers privation the most.

New PDM: Yes, Insulet still plans to upgrade its OmniPod PDM but that is gradually going to be phased out A customers are shifted to a more rotatable, smartphone app based scheme in the sexual climax years. Insulet's new chief technical military officer Shacey Petrovic says they'll file a 510k application with regulators later this year, for a new touchscreen Bluetooth-enabled PDM that will be mixed with the Dexcom G5 system.

Check up, Insulet's planning to possess Dexcom CGM technical school weaved into its OmniPod system?

What about those plans Insulet had back in 2013 about underdeveloped its possess CGM and working with an unnamed partner happening that? Last we heard, that tech was in animal trials and they were sightedness promising results. Course, that was earlier the Insulet management team totally turned over, so whatever happened to that?

"We are atomic number 102 longer pursuing the specific course of study," said Insulet's VP of Selling St. Christopher Gilbert. "We do continue to explore other potential partnerships and development opportunities with CGM companies, but we do not take over any public comments to share at this channelize."

OmniPod Counterfeit Pancreas: Big news show came on this the break of the day of the Insulet earnings call, with an annunciation that the OmniPod maker was partnered with Palo Alto startup Mode AGC (Machine-driven Glucose Control) to recrudesce its own OmniPod Artificial Pancreas organisation. We introduced Mode AGC last summertime when talking with co-founding father Dr. Jennifer Schneider, and it's electric to see this closed-loop algorithm being put into practice.

The algorithm will reside partially in the OmniPod itself, and the rest will be in the Cloud analyzing a person's D-Data. Human connected-trunk trials are prearranged to start afterward this year, with a pivotal trial in subsequent 2017.

On the earnings call, Insulet execs said they want to offer predictive low glucose suspend, and sooner or later the capability for the system to automatically adjust insulin-dosing based connected CGM readings.

We asked Insulet's Gilbert for more detail on what that means, and he tells us this:

"Mode AGC uses a posture that approximates an idiosyncratic's type 1 diabetes. It uses selective information from the past and present to predict the future. This information includes the patient's total daily dose of insulin, correction gene, insulin-to-carbohydrate ratio, current glucose, charge per unit of change of glucose, meals, etc. At one time it makes the anticipation it makes a conclusion on what to do with the insulin delivery dose and then recalculates the dose time and time again once again.

"The best analogy is that of playing chess. One uses past and current information to prognosis or predict what your opponent will do, so you make a move over and re-figure and make other move. In that elbow room, the Mode AGC algorithm will use past and current information to figure future blood glucose levels and make the necessary corrections along a day-after-day basis (e.g. 5-minute intervals) to insulin manner of speaking to optimise glycemic control while minimizing harmful events (i.e. hypoglycaemia and hyperglycemia)."

In footing of design, the system won't look specially unique, we'atomic number 75 told. It volition economic consumption the extant Pod platform to hasten the program and to observe the competitive advantage of this tubeless patch pump system.

Business Front: During the net profit predict connected Wednesday covering the Fourth Quarter and Full Yr 2015, Tandem Diabetes reported that it has 33,000 customers now victimisation all three of its touchscreen pumps — the original t:slenderize, the bigger 480-unit t:flex, and the t:slim down G4 jazz group. More than 15,400 pumps were sent out during 2015, which is an increase of 43% over the previous year.

Tandem Tubeless Wearable Patch Pump: We first heard approximately caller chatter most this t:sport back in early 2014 during earnings calls, and then it went off the radio detection and ranging until Summer 2015 when we heard Tandem Diabetes execs talking more about this during the Friends For Life conference.

This is what we know at this point about Tandem's plan for a sleek, OmniPod-alike tubeless pump that it describes Eastern Samoa a "hybrid" twist:

  • The t:lark will utilize the like t:slim technology to create a
    smaller, tubeless, tight patch heart
  • It's intentional for people WHO privation greater discretion and
    tractableness, no tubing, the ability to deliver insulin without touching the
    pump
  • Tandem anticipates it volition include a receiving set, touchscreen
    controller, and a limited, waterproof reservoir unit attachable to the skin (similar
    the Pod)
  • It will be half the size of the t:slim, with a shorter cannula
    (naturally)
  • The reservoir will also personify smaller, likely material possession 200 units
    (compared to the 300 in original t:slims and 480 units in the t:flex); Tandem
    believes this will be favorite, given the success Animas had with its smaller
    180-whole reservoir size
  • It will be controlled through either mobile app or a separate
    handheld device
  • Exploitation is current and clinical trials are planned for
    2016, with an FDA submission expected in 2017

Despite that last point, company execs say the t:disport is still in the early conceptual form, therefore no images are publicly available yet of the prototypes being developed.

Remote Updating: You may recall that last year, Tandem was talking about introducing something known as "Project Odyssey," a unprecedented way of life to upgrade our devices through software updates remotely from home, untold like we do now with smartphones. This plan is straightaway referred to more just as "Tandem Device Updater."

The first iteration of this program will offer software enhancements for early t:lose weight users, giving them the power to get the latest upgrades released in the past couple years that new t:slims straight off have shapely-in. Tandem bicycle plans to posit a 510k filing for this upgrade curriculum with the FDA by July with a Beta roll-KO'd shortly after that.

They state us the first looping North Korean won't allow the Bluetooth chip to be turned on in t:slim pumps, but that's the eventual end for Tandem. Turning connected the BT would allow for the pump to be compatible with the Dexcom G5 and future BT-enabled CGM generations. Unfortunately, the newest t:slender G4 combo product will quickly become outdated because IT doesn't have the BT chip deep down.

Tandem Artificial Pancreas: Tandem's first generation AP will use a predictive hypoglycaemia algorithm that the caller is developing internally. Tandem filed a pre-investigative submission subterminal year and hs been talking to the FDA astir plans to start a pivotal medical institution trial past the end of 2016, and ideally a commercial launch by the end of 2017.

The indorse propagation AP from Tandem would likely automatically increase or decrease insulin founded on the prognostic algorithm of CGM data. So IT seems Tandem's AP pipeline resembles what Medtronic has going with its 640G predictive device as well as its 670G hybrid closed loop. Of course, Tandem uses the Dexcom CGM tech and says its system of rules will be more desirable for patients because of the touchscreen design of In tandem pumps.

Pediatric and Provider Focus: Tandem plans to shortly file a 510k filing with the FDA to get its t:slim tech approved for kids as young equally age 6; it's currently authorised only for those 12 and older. The troupe is also acquiring ready to launch its then-called t:associate HCP, a edition of its software for healthcare providers that will allow for them to better manage patient information as intimately as demonstrate a severalise account for all of their t:slenderize users. A beta launch will happen in the coming weeks, with a broader HCP launch in mid-2016.

Dexcom's was in reality the first call we tuned into last week — after which we posted a brief news awake about a Customer Presentment that Dexcom Receivers may non sound audible alerts the like they'Re supposed to for High and Lowset blood sugars. Meanwhile, they offered other pipeline R&D updates:

Receiver: Dexcom remains confident that it will have a newly-designed receiver by the end of the year, arsenic we reported last in our D-Technical school 'Spectations 2016 post. Dexcom's new receiver will sport a touch screen and possibly an added feature with the G5 Mobile app that will display Insulin On Control panel (IOB) information federal official from partner pumps alike Animas Vibe, Tandem t:svelte, and Insulet OmniPod. Very coolheaded!

Inserter: The company is also excited about its hot insertion system that will establish toward the cease of the twelvemonth, which will provide United States CGM'ers with a smaller hand-held applicator that you right stick connected the skin, and push a button to insert (no plunger!). Dexcom CEO Kevin Sayer says this will be the ordinal new inserter the keep company has had since launching the CGM 11 years ago, and will be the biggest operational and manufacturing change the company has endured up to now.

G6: Plans as wel remain for Dexcom to file its next-generation G6 model later this year, with that hopefully gaining FDA approval and coming to market aside the end of 2016 operating theatre immature 2017. That next-gen sensor testament offer improved truth with a contrasting algorithmic rule, likely only one standardisation needful daily, and probably a 10-daytime assume (rather of the current FDA-authorized 7 days).

Sol D-peeps: What do you have in mind all the D-Tech that's coming down the pipeline in the all but future? Anything to add?